Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 191 matching drugs for FLT4 — including drugs targeting any of its 3 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
sunitinib FLT4 Direct yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FLT4 Direct 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FLT4 Direct 4
pembrolizumab, belzutifan, lenvatinib FLT4 Direct 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FLT4 Direct 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 FLT4 Direct 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FLT4 Direct 2
lenvatinib, pembrolizumab FLT4 Direct 2
lenvatinib, pembrolizumab, hyperpolarized 13c-pyruvate FLT4 Direct 2
mk-4830, pembrolizumab, carboplatin, pemetrexed, lenvatinib, paclitaxel, cisplatin, mk-4830a FLT4 Direct 2
nintedanib FLT4 Direct yes 2
nintedanib, pembrolizumab FLT4 Direct 2
pazopanib FLT4 Direct yes 2
pembrolizumab, lenvatinib FLT4 Direct 2
pembrolizumab, lenvatinib, oxaliplatin, capecitabine, leucovorin (or levoleucovorin), 5-fu FLT4 Direct 2
pembrolizumab/vibostolimab co-formulation, pembrolizumab, lenvatinib, 5-fluorouracil, cisplatin, paclitaxel, gemcitabine, carboplatin, docetaxel, bevacizumab, capecitabine, oxaliplatin FLT4 Direct 2
quality-of-life assessment, questionnaire administration, selpercatinib, therapeutic conventional surgery FLT4 Direct 2
regorafenib FLT4 Direct yes 2
regorafenib, laboratory biomarker analysis FLT4 Direct 2
sorafenib, administered orally, ct/mri FLT4 Direct 2
atezolizumab, tivozanib FLT4 Direct 1
axitinib FLT4 Direct yes 1
axitinib, avelumab FLT4 Direct 1
axitinib, axitinib plus lomustine FLT4 Direct 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib FLT4 Direct 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab FLT4 Direct 1
cisplatin, pemetrexed disodium, sorafenib FLT4 Direct 1
everolimus, sorafenib FLT4 Direct 1
everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging FLT4 Direct 1
fruquintinib, sintilimab FLT4 Direct 1
fruquintinib, tislelizumab, radiotherapy FLT4 Direct 1
gemcitabine, erlotinib, sorafenib FLT4 Direct 1
gemcitabine, placebo, sorafenib FLT4 Direct 1
gemcitabine, sorafenib, radiotherapy FLT4 Direct 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff FLT4 Direct 1
gemcitabine, sunitinib FLT4 Direct 1
h101, tislelizumab, lenvatinib FLT4 Direct 1
hydroxyurea, imatinib mesylate, vatalanib FLT4 Direct 1
imt-009, fruquintinib FLT4 Direct 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil FLT4 Direct 1
lenvatinib, bevacizumab FLT4 Direct 1
oxaliplatin, sorafenib FLT4 Direct 1
paclitaxel, irinotecan, pembrolizumab, mk-4830, lenvatinib, sacituzumab tirumotecan, antihistamine, h2 receptor antagonist, acetaminophen (or equivalent), dexamethasone (or equivalent) FLT4 Direct 1
pazopanib, 5-fu, oxaliplatin, leukovorin (flo) FLT4 Direct 1
pazopanib, lapatinib FLT4 Direct 1
pazopanib, placebo FLT4 Direct 1
pegilodecakin, paclitaxel or docetaxel and carboplatin or cisplatin, folfox (oxaliplatin/leucovorin/5-fluorouracil), gemcitabine/nab-paclitaxel, capecitabine, pazopanib, pembrolizumab, paclitaxel, nivolumab, gemcitabine/carboplatin FLT4 Direct 1
pembrolizumab, coformulation favezelimab/pembrolizumab, mk-4830, lenvatinib, irinotecan, paclitaxel FLT4 Direct 1
pembrolizumab, lenvatinib, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, paclitaxel FLT4 Direct 1
radiation therapy, temozolomide, sorafenib FLT4 Direct 1
regorafenib, lomustine FLT4 Direct 1
regorafenib, nivolumab, capeox, folfox regimen FLT4 Direct 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil FLT4 Direct 1
regorafenib, temozolomide FLT4 Direct 1
ryz101, everolimus, sunitinib, octreotide, lanreotide FLT4 Direct 1
selpercatinib FLT4 Direct yes 1
serplulimab, lenvatinib, paclitaxel/paclitaxel-albumin/paclitaxel liposome FLT4 Direct 1
sorafenib FLT4 Direct yes 1
sorafenib, erlotinb FLT4 Direct 1
sorafenib, rad001 FLT4 Direct 1
sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide FLT4 Direct 1
sunitinib, placebo FLT4 Direct 1
sunitinib, radiation FLT4 Direct 1
sunitinib, sunitinib FLT4 Direct 1
tace, lenvatinib, combined with tislelizumab group FLT4 Direct 1
tace, tislelizumab, lenvatinib FLT4 Direct 1
temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 FLT4 Direct 1
temozolomide, vatalanib, adjuvant therapy, radiation therapy FLT4 Direct 1
tivozanib FLT4 Direct 1
topotecan, pazopanib FLT4 Direct 1
topotecan, sorafenib FLT4 Direct 1
trc 105, sorafenib FLT4 Direct 1
vatalanib FLT4 Direct 1
vemurafenib, sorafenib FLT4 Direct 1
av9 FLT4 Direct yes 0
cabozantinib FLT4 Direct yes 0
cabozantinib s-malate FLT4 Direct yes 0
lenvatinib FLT4 Direct yes 0
lenvatinib mesylate FLT4 Direct yes 0
nintedanib esylate FLT4 Direct yes 0
pazopanib hydrochloride FLT4 Direct yes 0
sorafenib tosylate FLT4 Direct yes 0
sunitinib malate FLT4 Direct yes 0
tivozanib hydrochloride FLT4 Direct yes 0
vandetanib FLT4 Direct yes 0
sunitinib PDGFRA SSL via PDGFRA yes 5
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab FGFR2 SSL via FGFR2 4
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab PDGFRA SSL via PDGFRA 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) FGFR2 SSL via FGFR2 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) PDGFRA SSL via PDGFRA 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FGFR2 SSL via FGFR2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib PDGFRA SSL via PDGFRA 3
futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan FGFR2 SSL via FGFR2 3
pembrolizumab, belzutifan, lenvatinib FGFR2 SSL via FGFR2 3
pembrolizumab, belzutifan, lenvatinib PDGFRA SSL via PDGFRA 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FGFR2 SSL via FGFR2 2
bbi-355, erlotinib, futibatinib FGFR2 SSL via FGFR2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib FGFR2 SSL via FGFR2 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a FGFR2 SSL via FGFR2 2
gi-101, pembrolizumab (keytruda®), lenvatinib, local radiotherapy, gi-101a PDGFRA SSL via PDGFRA 2
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.